Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2019 2020 2021 2022 2023 2024 2025
Months
January February March April May June July August September October November December
Previous Archive
17 December 2020
Health sciences
The more than 100 medical students who graduated virtually from the University of the Free State (UFS) Faculty of Health Sciences on Monday (14 December), graduated with a pass rate of 98% in a tumultuous year dominated by the COVID-19 pandemic. The MB ChB class of 2020 – a total of 104 students from the School of Clinical Medicine – graduated virtually on Monday due to COVID-19.
The more than 100 medical students who graduated virtually from the University of the Free State (UFS) Faculty of Health Sciences on Monday (14 December), graduated with a pass rate of 98% in a tumultuous year dominated by the COVID-19 pandemic.

The MB ChB class of 2020 – a total of 104 students from the School of Clinical Medicine – graduated virtually on 14 December due to COVID-19. Another virtual graduation is scheduled for 4 January 2021.

An uncomfortable reality
Dr Lynette van der Merwe, undergraduate medical programme director in the School of Clinical Medicine at the UFS, congratulated the latest UFS doctors on their success. Said Dr Van der Merwe: “In a tumultuous year dominated by the COVID-19 pandemic, this group of final-year medical students refused to give in to the pressure and disruption of national lockdown, emergency remote teaching, an adjusted academic calendar, and frontline exposure as healthcare professionals in training.”  

“They persevered against all odds, faced up to an uncomfortable reality, and showed remarkable resilience.”

According to Dr Van der Merwe, the class of 2020 completed the gruelling five-year medical programme with a pass rate of 98,3%, impressing external examiners who commented on their respectful attitude towards patients and thorough knowledge and skill.  

“The School of Clinical Medicine and Faculty of Health Sciences are immensely proud of our new colleagues and look forward to their contribution to the future of healthcare in South Africa. This achievement would not have been possible without the unwavering commitment of the academic and support staff who guided our students and led the way for them to achieve a life-long dream.”  

“We look back with gratitude on a year that required more than the usual amount of adaptability, creativity, innovation, faith, patience, bravery, and endurance.  It is these qualities that set apart the doctors who graduate from the UFS, and those who train them,” says Dr Van der Merwe.

Hope for the future
She says while COVID-19 is still a harsh reality and the future holds much uncertainty, 2020 has shown that there is hope when we face challenges with grace under pressure, and a firm belief in our goals and values. “Class of 2020, may you continue to rise above fear, chaos and disappointment, may you take heart and walk your journey with strength, may you bring healing to our people and lead us well.”

Drs Kaamilah Joosub and Lynette Upman, who also graduated on Monday, were awarded the prestigious Bongani Mayosi Medical Students Academic Prize – a national award which aims to recognise final-year medical students who epitomise the academic, legendary, and altruistic life of the late Prof Mayosi. The awards are presented to final-year MB ChB students from all South African medical faculties. This is the first year it has been awarded.

• View the virtual graduation

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept